

Ji-Youn Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/15871/publications.pdf>

Version: 2024-02-01

51
papers

3,607
citations

201575

27
h-index

182361

51
g-index

52
all docs

52
docs citations

52
times ranked

4558
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039. | 13.9 | 691 |
| 2 | CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709. | 0.8 | 359 |
| 3 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402. | 0.8 | 320 |
| 4 | Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin. <i>Journal of Clinical Oncology</i> , 2006, 24, 2237-2244. | 0.8 | 293 |
| 5 | Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2007, 110, 138-147. | 2.0 | 188 |
| 6 | Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108. | 0.5 | 156 |
| 7 | A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1553-1560. | 3.2 | 117 |
| 8 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , 2019, 20, 1681-1690. | 5.1 | 92 |
| 9 | Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 115-120. | 0.9 | 91 |
| 10 | Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 59, 69-75. | 0.9 | 90 |
| 11 | JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009. | 0.8 | 74 |
| 12 | Association of <i>p53</i> codon 72 polymorphism and <i>MDM2</i> SNP309 with clinical outcome of advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008, 113, 799-807. | 2.0 | 67 |
| 13 | Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 636-648. | 0.5 | 67 |
| 14 | Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 475-483. | 1.1 | 62 |
| 15 | Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. <i>Oncotarget</i> , 2016, 7, 69450-69465. | 0.8 | 60 |
| 16 | The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 227-234. | 0.9 | 55 |
| 17 | A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 201-207. | 0.9 | 55 |
| 18 | Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512. | 0.8 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 137-142. | 0.9 | 46 |
| 20 | Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3488-3494. | 0.8 | 45 |
| 21 | Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 85, 161-167. | 0.9 | 43 |
| 22 | Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1001-1011. | 1.3 | 43 |
| 23 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567. | 0.5 | 43 |
| 24 | A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. <i>Cancer</i> , 2011, 117, 2178-2185. | 2.0 | 40 |
| 25 | PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 627. | 1.1 | 40 |
| 26 | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 283. | 1.2 | 32 |
| 27 | Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRG1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802. | 0.8 | 32 |
| 28 | A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2003, 98, 1918-1924. | 2.0 | 30 |
| 29 | A phase II study of nintedanib in patients with relapsed small cell lung cancer. <i>Lung Cancer</i> , 2016, 96, 108-112. | 0.9 | 30 |
| 30 | Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008, 113, 388-395. | 2.0 | 27 |
| 31 | Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 293-299. | 0.9 | 24 |
| 32 | Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2- <i>NRG1</i> -Mediated Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2024-2033. | 1.9 | 24 |
| 33 | Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2006, 106, 873-880. | 2.0 | 23 |
| 34 | Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 151, 8-15. | 0.9 | 23 |
| 35 | DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. <i>Cancer</i> , 2011, 117, 3201-3208. | 2.0 | 22 |
| 36 | EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an <i>NRG1</i> fusion. <i>Lung Cancer</i> , 2018, 124, 71-75. | 0.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5909-14. | 3.2 | 19 |
| 38 | Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2010, 10, 86-93. | 0.9 | 15 |
| 39 | Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1039-1045. | 0.5 | 14 |
| 40 | Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2005, 104, 2759-2765. | 2.0 | 13 |
| 41 | A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 465-472. | 1.3 | 12 |
| 42 | The Correlation Between Gastric Cancer Screening Method and the Clinicopathologic Features of Gastric Cancer. <i>Medical Oncology</i> , 2003, 20, 265-270. | 1.2 | 6 |
| 43 | Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224. | 0.6 | 6 |
| 44 | A Phase II Study of Dose-Intensified Weekly Concomitant Administration of Cisplatin and Irinotecan in Chemo-naive Patients with Extensive-Disease Small-Cell Lung Cancer. <i>Medical Oncology</i> , 2005, 22, 281-290. | 1.2 | 4 |
| 45 | Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib. <i>Journal of Korean Medical Science</i> , 2013, 28, 1595. | 1.1 | 4 |
| 46 | ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 678-687. | 1.3 | 3 |
| 47 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2459-2469. | 1.2 | 3 |
| 48 | Symptom perception and functioning in patients with advanced cancer. <i>PLoS ONE</i> , 2021, 16, e0245987. | 1.1 | 2 |
| 49 | ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9601-9601. | 0.8 | 1 |
| 50 | Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 1512. | 1.7 | 1 |
| 51 | A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3105-3105. | 0.8 | 0 |